Related Experiment Video
Updated: Jun 29, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
[Similarity of biotechnology-derived drugs: regulatory framework and specificity]
1Service de pharmacie, CHU Saint-Antoine, AP-HP, 184, rue du Faubourg, 75012 Paris, France. Jean-louis.prugnaud@sat.ap-hop-paris.fr
Abstract:
Directive 2004/27/EC, issued by the European commission specifies the conditions by which marketing approval can be awarded for a biosimilar drug, whose structure is the closest possible to that of an already marketed biotechnology-drug. This specific regulation differs in more than one point from that applied to classical generic products. Others conditions beyond the sole demonstration of in vivo bioequivalence should be satisfied to ensure prudent, i.e., without risk to the patient, therapeutic substitution.
More Related Videos
07:43A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears
Published on: July 14, 2023
06:26Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioequivalence: Overview
Pharmaceutical Equivalents
Bioequivalence studies: Biowaivers
Drug Regulation